GlassScriptPhysician profile
Raluca Ioanid
NPI 1831479054
$4,835.28
in general payments reported to CMS, 2019-2025
57 companies · $3,473 in 2025
The $3,473 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $228 · 2024: $1,134 · 2025: $3,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,437 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,437.34 |
| Education | $397.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $492.22 | 2024-2025 | Imfinzi, Lynparza, Tagrisso |
| Janssen Biotech, INC. | $340.64 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $291.75 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $235.49 | 2025 | Xtandi |
| Genentech USA, INC. | $179.21 | 2025 | Venclexta, Polivy, Itovebi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.19 | 2023-2025 | Jardiance |
| Jazz Pharmaceuticals INC. | $155.21 | 2024-2025 | |
| Array Biopharma INC | $147.48 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Daiichi Sankyo INC. | $146.83 | 2024-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $146.64 | 2024-2025 | Alunbrig, Fruzaqla, Advate |
| Incyte Corporation | $127.33 | 2024-2025 | Jakafi, Monjuvi, Niktimvo |
| Aveo Pharmaceuticals, INC. | $120.25 | 2025 | |
| Novartis Pharmaceuticals Corporation | $113.21 | 2024-2025 | |
| Pfizer INC. | $107.83 | 2024-2025 | |
| Stemline Therapeutics INC. | $105.89 | 2024-2025 | Orserdu, Elzonris |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $97.70 | 2024-2025 | Pyrukynd |
| Lilly USA, LLC | $93.14 | 2024 | Jaypirca, Verzenio |
| Genmab U.S., INC. | $89.02 | 2024-2025 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $71.61 | 2024-2025 | Libtayo |
| Taiho Oncology, INC. | $71.46 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $68.13 | 2025 | Qinlock, Tgct, Romvimza |
| Octapharma USA, INC. | $68.13 | 2024-2025 | Octagam Immune Globulin (Human) |
| Kite Pharma, INC. | $65.98 | 2024-2025 | Yescarta |
| Eisai INC. | $63.70 | 2025 | |
| Caris Mpi, INC. | $63.32 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $63.01 | 2025 | Loqtorzi |
| Bayer Healthcare Pharmaceuticals INC. | $61.79 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $60.07 | 2025 | Xpovio |
| Geron Corporation | $54.47 | 2025 | Rytelo |
| Abbott Laboratories | $53.85 | 2023 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $51.93 | 2024 | Poteligeo |
| Myriad Genetic Laboratories, INC. | $50.75 | 2023 | Myrisk |
| Exelixis INC. | $46.43 | 2025 | Cabometyx |
| Celgene Corporation | $46.17 | 2025 | Opdivo, Reblozyl |
| Novocure INC. | $44.63 | 2024-2025 | Optune Lua (Novottf-200t) |
| Blueprint Medicines Corporation | $44.46 | 2024 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $44.24 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Accord Healthcare, INC. | $43.43 | 2025 | |
| Spectrum Pharmaceuticals INC. | $42.88 | 2025 | Rolvedon |
| Servier Pharmaceuticals LLC | $41.19 | 2024-2025 | |
| Legend Biotech USA INC. | $37.35 | 2025 | Carvykti |
| Biocon Biologics INC | $35.19 | 2025 | Ogivri |
| Beone Medicines USA, INC. | $31.41 | 2025 | Brukinsa |
| Glaxosmithkline, LLC. | $31.16 | 2025 | Ojjaara |
| Alexion Pharmaceuticals, INC. | $30.02 | 2024-2025 | Ultomiris |
| Immunocore Limited | $29.19 | 2024 | Kimmtrak |
| Emd Serono, INC. | $28.73 | 2025 | |
| Iovance Biotherapeutics, INC. | $28.00 | 2025 | Amtagvi |
| Abbvie INC. | $26.66 | 2024 | |
| Sobi, INC | $25.28 | 2024 | |
| Adc Therapeutics America, INC. | $23.06 | 2025 | |
| Acrotech Biopharma INC. | $21.66 | 2025 | Beleodaq |
| Tersera Therapeutics LLC | $21.50 | 2025 | Zoladex |
| E.R. Squibb & Sons, L.L.C. | $20.88 | 2025 | Opdivo |
| Puma Biotechnology, INC. | $20.72 | 2025 | |
| Sun Pharmaceutical Industries INC. | $20.04 | 2025 | |
| Gilead Sciences, INC. | $17.77 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raluca Ioanid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.